Wurus Biosciences
Wurus Biosciences provides an AI-powered microbial discovery platform that combines high-throughput culturomics, precision isolation, and genomic analysis to recover over 80% of live bacteria from complex samples. The company's end-to-end workflow supports strain selection through commercial application, with a 99% target culture success rate and the industry's shortest turnaround time.
- Biotechnology
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Data & Analytics
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional microbial research methods can only culture a fraction of the living bacteria present in complex biological samples, leaving the vast majority of the microbiome unexplored. This limitation hinders the discovery of novel strains, the development of live biotherapeutic products, and a comprehensive understanding of microbial ecosystems.
Solution
Wurus Biosciences provides an integrated microbial discovery platform that combines high-throughput culturomics, precision isolation, and AI-enabled analytics to recover living microbes from complex samples and convert them into actionable data. The platform uses proprietary culture conditions designed to recover over 80% of live bacteria from any sample, substantially outperforming standard methods. Once isolated, strains undergo strain-level identification through metagenomic, whole-genome, and comparative genomic analysis, as well as antimicrobial screening. This workflow supports product development from initial strain selection through performance validation and commercial application, enabling researchers and pharmaceutical companies to accelerate microbiome-based innovation.
Target Audience
Primary customers are microbiome researchers, pharmaceutical and biotechnology companies, and academic institutions engaged in microbial discovery, live biotherapeutic product development, and microbiome-based therapeutic innovation.
Features
- Proprietary high-throughput culturomics technology with culture conditions enabling recovery of over 80% of live bacteria from any sample
- 99% target culture success rate with the shortest turnaround time in the industry
- Precision isolation of targeted microorganisms from complex samples including gut, animal, and environmental microbiomes
- Genomic analysis suite covering metagenomics, whole genome sequencing, comparative genomics, and antimicrobial screening
- End-to-end product development support from strain selection to performance testing and commercial-scale applications
- AI-powered analytics that transform isolated microbial strains into actionable datasets for research and product development